Glyphic Biotechnologies

Founded in 2021 and headquartered in Berkeley, California, Glyphic Biotechnologies exists to fundamentally rewrite the rules of proteomics. The company is developing Protein Sequencing by Expansion (ProSE™), the first truly de novo high-throughput proteome sequencing technology capable of discriminating all 20 amino acids and post-translational modifications with single-molecule sensitivity. Glyphic's platform leverages spatial expansion of amino acids to enable massively parallel proteome sequencing, unlocking critical first-in-class therapies and deeper insights into biology.